Low-dose valaciclovir prophylaxis against cytomegalovirus disease in renal transplant recipients.
High-dose valaciclovir at up to 8 g/day has been shown to be effective in prophylaxis against cytomegalovirus (CMV) disease in renal transplant recipients. We report our experience with low-dose valaciclovir prophylaxis of up to 3 g/day, adjusted to creatinine clearance. A group of patients at high...
| Main Authors: | , , , , , , , |
|---|---|
| פורמט: | Journal article |
| שפה: | English |
| יצא לאור: |
2003
|
| _version_ | 1826298256462708736 |
|---|---|
| author | Reddy, S Handa, A Tan, L Devaney, A Hughes, D Mason, P Friend, P Darby, C |
| author_facet | Reddy, S Handa, A Tan, L Devaney, A Hughes, D Mason, P Friend, P Darby, C |
| author_sort | Reddy, S |
| collection | OXFORD |
| description | High-dose valaciclovir at up to 8 g/day has been shown to be effective in prophylaxis against cytomegalovirus (CMV) disease in renal transplant recipients. We report our experience with low-dose valaciclovir prophylaxis of up to 3 g/day, adjusted to creatinine clearance. A group of patients at high risk of developing CMV disease who received prophylaxis were selected as the study group. This included all CMV-positive patients who received antilymphocyte therapy (R+, n=20) and all CMV-negative recipients of CMV-positive organs (D+R-, n=15). D+R- patients receiving antilymphocyte therapy were excluded, as most of the patients in the control group had received ganciclovir prophylaxis. A historical control group was used, which consisted of patients who did not receive prophylaxis. Low-dose valaciclovir prophylaxis resulted in a statistically significant decrease (8.5 vs 37%, P=0.004) in CMV disease in the study group at 6 months. On subgroup analysis the decrease was statistically significant only in the R+ group (5 vs 45%, P=0.003), not in the D+R- group (13.3 vs 26.6%, P=0.651). Low-dose valaciclovir prophylaxis seems to be adequate for R+ patients receiving antilymphocyte therapy. The role of low-dose valaciclovir prophylaxis needs to be assessed further in a prospective trial. |
| first_indexed | 2024-03-07T04:44:05Z |
| format | Journal article |
| id | oxford-uuid:d2a3ab76-c860-4db9-aa7c-fbe82de98ba2 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T04:44:05Z |
| publishDate | 2003 |
| record_format | dspace |
| spelling | oxford-uuid:d2a3ab76-c860-4db9-aa7c-fbe82de98ba22022-03-27T08:05:29ZLow-dose valaciclovir prophylaxis against cytomegalovirus disease in renal transplant recipients.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:d2a3ab76-c860-4db9-aa7c-fbe82de98ba2EnglishSymplectic Elements at Oxford2003Reddy, SHanda, ATan, LDevaney, AHughes, DMason, PFriend, PDarby, CHigh-dose valaciclovir at up to 8 g/day has been shown to be effective in prophylaxis against cytomegalovirus (CMV) disease in renal transplant recipients. We report our experience with low-dose valaciclovir prophylaxis of up to 3 g/day, adjusted to creatinine clearance. A group of patients at high risk of developing CMV disease who received prophylaxis were selected as the study group. This included all CMV-positive patients who received antilymphocyte therapy (R+, n=20) and all CMV-negative recipients of CMV-positive organs (D+R-, n=15). D+R- patients receiving antilymphocyte therapy were excluded, as most of the patients in the control group had received ganciclovir prophylaxis. A historical control group was used, which consisted of patients who did not receive prophylaxis. Low-dose valaciclovir prophylaxis resulted in a statistically significant decrease (8.5 vs 37%, P=0.004) in CMV disease in the study group at 6 months. On subgroup analysis the decrease was statistically significant only in the R+ group (5 vs 45%, P=0.003), not in the D+R- group (13.3 vs 26.6%, P=0.651). Low-dose valaciclovir prophylaxis seems to be adequate for R+ patients receiving antilymphocyte therapy. The role of low-dose valaciclovir prophylaxis needs to be assessed further in a prospective trial. |
| spellingShingle | Reddy, S Handa, A Tan, L Devaney, A Hughes, D Mason, P Friend, P Darby, C Low-dose valaciclovir prophylaxis against cytomegalovirus disease in renal transplant recipients. |
| title | Low-dose valaciclovir prophylaxis against cytomegalovirus disease in renal transplant recipients. |
| title_full | Low-dose valaciclovir prophylaxis against cytomegalovirus disease in renal transplant recipients. |
| title_fullStr | Low-dose valaciclovir prophylaxis against cytomegalovirus disease in renal transplant recipients. |
| title_full_unstemmed | Low-dose valaciclovir prophylaxis against cytomegalovirus disease in renal transplant recipients. |
| title_short | Low-dose valaciclovir prophylaxis against cytomegalovirus disease in renal transplant recipients. |
| title_sort | low dose valaciclovir prophylaxis against cytomegalovirus disease in renal transplant recipients |
| work_keys_str_mv | AT reddys lowdosevalaciclovirprophylaxisagainstcytomegalovirusdiseaseinrenaltransplantrecipients AT handaa lowdosevalaciclovirprophylaxisagainstcytomegalovirusdiseaseinrenaltransplantrecipients AT tanl lowdosevalaciclovirprophylaxisagainstcytomegalovirusdiseaseinrenaltransplantrecipients AT devaneya lowdosevalaciclovirprophylaxisagainstcytomegalovirusdiseaseinrenaltransplantrecipients AT hughesd lowdosevalaciclovirprophylaxisagainstcytomegalovirusdiseaseinrenaltransplantrecipients AT masonp lowdosevalaciclovirprophylaxisagainstcytomegalovirusdiseaseinrenaltransplantrecipients AT friendp lowdosevalaciclovirprophylaxisagainstcytomegalovirusdiseaseinrenaltransplantrecipients AT darbyc lowdosevalaciclovirprophylaxisagainstcytomegalovirusdiseaseinrenaltransplantrecipients |